Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557098 · ClinicalTrials.gov registry record · Phase 2
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Hematological Malignancies, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT04557098 is a Phase 2 study of Hematological Malignancies that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 194 participants, below the 764-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04557098, a Phase 2 study of Hematological Malignancies, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Conditions Studied
Interventions
- DRUG Teclistamab
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - UZ GENT - Ghent
- Universitaire Ziekenhuizen Leuven - Leuven
- Peking University First Hospital - Beijing
- West China Hospital Si Chuan University - Chengdu
- Sun Yat -Sen University Cancer Center - Guangzhou
- First affiliated Hospital of Zhejiang University - Hangzhou
California
- City of Hope - Duarte
- University of California San Francisco - San Francisco
- Stanford University Medical Center - Stanford
New York
- Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects - New York
- Memorial Sloan-Kettering Cancer Center - New York
Alberta
- Arthur J E Child Comprehensive Cancer Centre - Calgary
- Cross Cancer Institute - Edmonton
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Winship Cancer Institute Emory University - Atlanta
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2027-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557098
The ClinicalTrials.gov registry entry for NCT04557098 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 764-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (75% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Teclistamab is the first listed.
NCT04557098 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04557098 about?
NCT04557098 is a clinical study titled "A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
What is the current status of trial NCT04557098?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2020-09-17. Estimated completion is 2027-05-28.
What conditions does trial NCT04557098 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT04557098?
The interventions under investigation include: Teclistamab (DRUG).
Who is sponsoring clinical trial NCT04557098?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04557098 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
COMPLETED · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.